Don't ya just hate companies growing like this while everybody else is floundering <ggg>...seriously though....look at their increases from last year...while every company was struggling, this little gem was seeing 200% increases in revenue......news has been nothing but positive......and we are barely getting started....imagine one day in the near future when their service is MANDATORY and is also covered by insurance...and even if it's not....$200 intial storage fee and $50 a year is nothing when it compares to the life of your child....and lets not even think about security....within your umbilical cord is your footprint of life...dna.....the medical benefits are staggering, but so are the security measures.....in a way it would be like fingerprinting every newborn baby...then later when a rape occurs, or other ghastly deed, and all they find is a flake of skin or a hair.....a giant data base will pinpoint the culprit....but I am getting ahead of myself here....the main benefit is plain and simple......the cost is minimal, the benefits staggering as you could be saving your childs life, and there is not a single negative...not a one.....look how low the volume is....with growth rates like this, in this type of climate, big money will eventuall notice and then, look out above <ggg>
Don't ya just hate companies growing like this while everybody else is floundering <ggg>
Record Revenues Continue at CRYO-CELL; Company Announces 11th Successive Monthly Increase
CLEARWATER, Fla., Nov. 1 /PRNewswire/ -- Wanda D. Dearth, President and Chief Operating Officer of CRYO-CELL International, Inc. (Nasdaq: CCEL) announced today that the Company achieved its eleventh consecutive record sales month for its umbilical cord blood (U-Cord)(TM) preservation program.
(Photo: newscom.com )
Highlights for October include:
* October 2001 revenues of $576,907 exceeded September 2001 sales of
546,754, a 5.5% month over month increase.
* October 2001 revenues compare to $206,545 in October 2000,
representing an increase of 179%.
* 2001 year-to-date sales are $5,170,792 compared to $1,878,303 for
the same eleven month period during 2000, representing a 175%
year-to-year increase. YTD 2001 revenues include $750,000 from the
sale of a Revenue Sharing Agreement during May; discounting this
impact, YTD sales from the U-Cord program increased 135 % on a
year-to-year basis.
In the third quarter 10Q filed on October 12, the Company reported its second consecutive profitable quarter. According to Jill Taymans, CRYO-CELL's Chief Financial Officer, "The Company's sales volume in both September and October have enabled us to be profitable in our core cord blood preservation business with positive cash flow."
According to Daniel D. Richard, Chairman and Chief Executive Officer, the above sales do not include the "other income" we report quarterly from the Company's international license fees and/or on-going entitlements from Europe, Mexico/Central America and Israel/Middle East. "Europe is also experiencing record sales, which is our motivation for recently negotiating an option to purchase an additional 60% of their company," Mr. Richard stated.
CRYO-CELL is America's fastest growing and largest exclusive, private U-Cord stem cell preservation firm. The Company pioneered affordable cord blood stem cell storage. Its initial fees are 1/4 to 1/5 the cost of many of its major competitors, and its $50 annual fee is fixed for specimens already in storage.
CRYO-CELL is a publicly traded company (NASDAQ symbol ... C C E L). CRYO-CELL Web site: www.cryo-cell.com. CRYO-CELL Europe Web site: www.cryoc.com. CRYO-CELL Mexico Web site: www.cryo-cell.com.mx.
Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward looking statements or paragraphs. Readers should carefully review the risk factors described in other
documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE CRYO-CELL International, Inc.
CO: CRYO-CELL International, Inc.
ST: Florida
IN: OTC MTC BIO
SU: SLS
11/01/2001 15:06 EST prnewswire.com
Record Revenues Continue at CRYO-CELL; Company Announces 11th Successive Monthly Increase
CLEARWATER, Fla., Nov. 1 /PRNewswire/ -- Wanda D. Dearth, President and Chief Operating Officer of CRYO-CELL International, Inc. (Nasdaq: CCEL) announced today that the Company achieved its eleventh consecutive record sales month for its umbilical cord blood (U-Cord)(TM) preservation program.
(Photo: newscom.com )
Highlights for October include:
* October 2001 revenues of $576,907 exceeded September 2001 sales of
546,754, a 5.5% month over month increase.
* October 2001 revenues compare to $206,545 in October 2000,
representing an increase of 179%.
* 2001 year-to-date sales are $5,170,792 compared to $1,878,303 for
the same eleven month period during 2000, representing a 175%
year-to-year increase. YTD 2001 revenues include $750,000 from the
sale of a Revenue Sharing Agreement during May; discounting this
impact, YTD sales from the U-Cord program increased 135 % on a
year-to-year basis.
In the third quarter 10Q filed on October 12, the Company reported its second consecutive profitable quarter. According to Jill Taymans, CRYO-CELL's Chief Financial Officer, "The Company's sales volume in both September and October have enabled us to be profitable in our core cord blood preservation business with positive cash flow."
According to Daniel D. Richard, Chairman and Chief Executive Officer, the above sales do not include the "other income" we report quarterly from the Company's international license fees and/or on-going entitlements from Europe, Mexico/Central America and Israel/Middle East. "Europe is also experiencing record sales, which is our motivation for recently negotiating an option to purchase an additional 60% of their company," Mr. Richard stated.
CRYO-CELL is America's fastest growing and largest exclusive, private U-Cord stem cell preservation firm. The Company pioneered affordable cord blood stem cell storage. Its initial fees are 1/4 to 1/5 the cost of many of its major competitors, and its $50 annual fee is fixed for specimens already in storage.
CRYO-CELL is a publicly traded company (NASDAQ symbol ... C C E L). CRYO-CELL Web site: www.cryo-cell.com. CRYO-CELL Europe Web site: www.cryoc.com. CRYO-CELL Mexico Web site: www.cryo-cell.com.mx.
Forward-Looking Statement
Statements wherein the terms "believes", "intends", "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward looking statements or paragraphs. Readers should carefully review the risk factors described in other
documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE CRYO-CELL International, Inc.
CO: CRYO-CELL International, Inc.
ST: Florida
IN: OTC MTC BIO
SU: SLS
11/01/2001 15:06 EST prnewswire.com |
